EXEL

Exelixis Grabs 90% of First Place

Doctor sitting at a table talking to a patient

Exelixis (NASDAQ: EXEL) is proving that sometimes being second-best can work out just fine, especially when you're in the business of treating a disease like kidney cancer -- a condition for which no cure has been found, so patients' cancers will eventually progress on the first drug they take. Bristol-Myers Squibb 's (NYSE: BMY) Opdivo and Yervoy combination may grab many of those patients initially, but 90% of those who progress on that regimen are moving on to Exelixis' Cabometyx. And its strong position as a second-line treatment certainly helped boost the company's fourth-quarter revenue.

Exelixis results: The raw numbers

Data source: Exelixis.

What happened this quarter?

  • Cabometyx sales grew 8% sequentially. Some of that was due to an increase in inventory, and a price hike helped as well, but demand was still up 6% quarter over quarter, an acceleration from the 5% increase seen between the second and third quarters.
  • While Cabometyx sales provide the majority of Exelixis' revenue, the company also booked $27.9 million in milestones from its partners Ipsen and Takeda; $12.3 million of royalties from Ipsen for overseas sales of Cabometyx; $3.4 million of profit-sharing royalties from Roche 's Genentech unit for sales of Cotellic; and $8.8 million of additional collaboration revenue.
  • In January, Exelixis' partner, Daiichi Sankyo, got Minnebro approved in Japan to treat high blood pressure, setting up a $20 million milestone payment when the drug launches there, as well as low double-digit royalties on sales.
  • Also in January, the FDA approved Cabometyx for liver cancer.
  • In conjunction with the earnings report, Exelixis announced that its restarted drug-discovery program has produced its first drug candidate, XL092, which is ready to enter the clinic.

What management had to say

Senior Vice President of Commercial PJ Haley talked about Cabometyx's recent approval as a treatment for liver cancer (hepatocellular carcinoma, HCC), how it might compete with other new immuno-oncology (IO) and tyrosine kinase inhibitor (TKI) drugs, as well as how Exelixis can leverage the previous approval for kidney cancer (renal cell carcinoma, RCC):

President and CEO Michael Morrissey highlighted plans for additional acquisitions or licensing deals to pad the company's pipeline:

Looking forward

Management didn't give revenue guidance, which seems completely reasonable given the dynamic nature of the liver cancer market and additional potential kidney cancer competition from Merck 's Keytruda, which is in the same class as Bristol-Myers's Opdivo.

But as long as Cabometyx can continue to take market share from the smaller players, investors should be content with the drug sitting in second place for kidney cancer, especially since its ongoing battle with Bristol-Myers may turn into a commercial partnership. In addition, a late-stage clinical trial called CheckMate 9ER testing Cabometyx plus Bristol's Opdivo in first-line kidney cancer patients is scheduled to read out in the second half of this year.

10 stocks we like better than Exelixis

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Exelixis wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of January 31, 2019

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Exelixis. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.